medRxiv preprint doi: https://doi.org/10.1101/19009274; this version posted October 16, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

BRAF mutation testing of MSI CRCs in Lynch syndrome diagnostics: performance and
efficiency according to patient`s age
Hendrik BlÃ¤ker*1, Saskia Haupt2, Monika Morak3,4, Elke Holinski-Feder3,4, Alexander Arnold5,
David Horst5, Julia Sieber-Frank6, Florian Seidler6, Moritz von Winterfeld7, Elizabeth Alwers8,
Jenny Chang-Claude9, Hermann Brenner8,10,11, Wilfried Roth12, Christoph Engel13, Markus
LÃ¶ffler13, Gabriela MÃ¶slein14, Hans-Konrad Schackert15, JÃ¼rgen Weitz15, Claudia Perne16,17,
Stefan Aretz16,17, Robert HÃ¼neburg17, Wolff Schmiegel18, Deepak Vangala18, Nils Rahner19,
Verena Steinke-Lange3,4, Vincent Heuveline2, Magnus von Knebel Doeberitz6, Aysel
Ahadova**6, Michael Hoffmeister**8, Matthias Kloor**6 and the German Consortium for
Familial Intestinal Cancer
* Corresponding author
** shared senior authorship

Affiliations:
1
Institute of Pathology, University Hospital Leipzig, Leipzig, Germany;
2
Engineering Mathematics and Computing Lab (EMCL), Interdisciplinary Center for
Scientific Computing (IWR), Heidelberg University, Heidelberg, Germany;
3
Medizinische Klinik und Poliklinik IV, Campus Innenstadt, Klinikum der UniversitÃ¤t
MÃ¼nchen, Munich, Germany;
4
MGZ â€“ Medical Genetics Center, Munich, Germany;
5
Institute of Pathology, Charite Berlin, Berlin, Germany;
6
Department of Applied Tumor Biology, University Hospital Heidelberg, Cooperation
Unit Applied Tumor Biology, German Cancer research Center (DKFZ), and Molecular
Medicine Partnership Unit (MMPU), University Hospital Heidelberg, Heidelberg, Germany
7
Department of General Pathology, Institute of Pathology, University Hospital
Heidelberg
8
Division of Clinical Epidemiology and Aging Research, German Cancer Research
Center (DKFZ) Heidelberg, Germany
9
Division of Cancer Epidemiology, Unit of Genetic Epidemiology, German Cancer
Research Center (DKFZ) Heidelberg, Germany
10
Division of Preventive Oncology, German Cancer Research Center (DKFZ) and
National Center for Tumor Diseases (NCT) Heidelberg, Germany
11
German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ),
Heidelberg, Germany
12
Institute of Pathology, University Hospital Mainz, Germany;
13
Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig,
Leipzig, Germany;
14
Center for Hereditary Tumors, Helios University Hospital Wuppertal, University of
Witten/Herdecke, Wuppertal, Germany
15
Department of Surgery, University Hospital Carl Gustav Carus, Technical University
Dresden,
Dresden,
Germany.
NOTE: This preprint
reports
new research that has not been certified by peer review and should not be used to guide clinical practice.
16
Institute of Human Genetics, University of Bonn, Bonn, Germany;

medRxiv preprint doi: https://doi.org/10.1101/19009274; this version posted October 16, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

17
Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany;
18
Department of Medicine, Knappschaftskrankenhaus, Ruhr-University Bochum,
Bochum, Germany;
19
Medical Faculty, Institute of Human Genetics, Heinrich-Heine University, DÃ¼sseldorf,
Germany
Grant support:
The study was supported by Wilhelm Sander Foundation (2016.056.1), and German
Research Foundation (Deutsche Forschungsgemeinschaft, DFG; KFO227, KL2354).

Correspondence:
Hendrik BlÃ¤ker
Institute of Pathology
University Hospital Leipzig
LiebigstraÃŸe 26
GebÃ¤ude G
04103 Leipzig, Germany
Tel.: +49 (341) 97 - 15000
E-Mail: hendrik.blaeker@medizin.uni-leipzig.de
Disclosures:
The authors have no conflict of interests.
Authorsâ€™ contributions:
Study concept and design: HB, MK, AAh, MvW, MH, SH, MvKD.
Sample acquisition:HB, MM, EHF, DH, GM, HKS, CP, SA, RH, WS, DV, NR, VSL.
Data interpretation: HB, SH, MM, VSL, MvKD, AAh, MH, MK.
Statistical analysis: SH, EA, JCC, HB, CE, ML, VH, MH.
Acquisition of data: HB, SH, AAh, MK, MH, JSF, FS, AAr.
Writing of manuscript: HB, SH, AAh, MH, MK.
Review and/or revision of the manuscript: all authors

medRxiv preprint doi: https://doi.org/10.1101/19009274; this version posted October 16, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Abstract

Background and aims
BRAF V600E mutations have been reported to be associated with sporadic microsatelliteunstable (MSI) colorectal cancer (CRC), while rarely detected in CRCs of Lynch syndrome (LS)
patients. Therefore, current international diagnostic guidelines recommend somatic BRAF
mutation testing in MLH1-deficient MSI CRC patients to exclude LS. As sporadic BRAF-mutant
MSI CRC is a disease of the elderly, while LS-associated CRC usually occurs at younger age,
we hypothesized that the efficacy of BRAF testing in LS diagnostics may be age-dependent.
Methods
We systematically compared the prevalence of BRAF V600E mutations in LS-associated CRCs
and MSI CRCs from population-based cohorts in different age groups as available from
published studies, databases, and population-based patient cohorts. Cost calculations and
sensitivity analysis of the BRAF testing for exclusion of LS was performed.
Results
Among 969 MSI CRCs from LS mutation carriers from the literature and German HNPCC
Consortium, 15 (1.6%, 95% CI: 0.9-2.6%) harbored BRAF mutations. 6/7 LS patients with
BRAF-mutant CRC and reported age were <50 years. Among unselected MSI CRCs, 44.8%
(339/756) harbored BRAF mutations, 92.3% (313/339) of which were detected in patients
>60 years. In MSI CRC patients <50, BRAF mutations were detected only in 0.6% (2/339), and
the inclusion of BRAF testing led to increased costs and higher risk of missing LS patients
(1.2%) compared to other age groups.
Conclusion
BRAF testing in patients <50 years is cost-inefficient and carries the highest risk of missing LS
patients among different age groups. We suggest direct referral of MSI CRC patients <50
years to genetic counseling without prior BRAF testing.
Keywords: colorectal cancer, microsatellite instability, Lynch syndrome, BRAF testing.

medRxiv preprint doi: https://doi.org/10.1101/19009274; this version posted October 16, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Lynch Syndrome (LS) is the most common hereditary colorectal cancer (CRC) syndrome,
accounting for 2-3% of all CRC cases1,2. LS is caused mainly by heterozygous germline
mutations in one of the DNA mismatch repair (MMR) genes (MLH1, MSH2, PMS2, MSH6)3.
Due to the inactivation of MMR proteins by a second somatic hit, LS-associated cancers
show MMR protein deficiency and microsatellite instability (MSI). Therefore, testing for MSI
and MMR protein deficiency is commonly the first step in LS diagnostics 4. However, MSI in
tumor cells does not prove LS; in fact, most MSI tumors occur sporadically 5. Sporadic MSI
tumors commonly occur in older patients with marked predominance for female gender,
lack MLH1 protein expression due to MLH1 promoter methylation, and are strongly
associated with the CpG island methylator phenotype (CIMP) and the serrated route of
carcinogenesis related to the activating hotspot oncogenic mutations in the BRAF gene
(c.1799 T>A p.Val600Glu, also called V600E)6. MLH1-deficient MSI CRCs per se are therefore
not highly suggestive of LS, particularly those diagnosed in the elderly.
With the expansion of recommendations to perform tumor testing for potential LS not only
in patients fulfilling Bethesda criteria7,8, but also in all CRCs/CRCs diagnosed before the age
of
709
(NICE
guidelines:
https://www.nice.org.uk/guidance/dg27/chapter/1Recommendations), the need for additional markers differentiating LS from sporadic MSI
CRC increased. Such markers would reduce the number of MSI CRC patients referred to
germline mutation analysis, thus also reducing patientsâ€™ mental stress and healthcare
costs7,10,11. In an early attempt to identify such molecular markers, Deng et al. 12 suggested
the BRAF V600E mutation as a possible marker occurring in sporadic, but not LS-associated
MSI CRC.
The potential diagnostic value of BRAF V600E mutations to exclude LS has further been
supported by studies reporting a specificity of 100%11,13,14. Others, however, occasionally
detected BRAF mutations in LS-associated CRC15-17, according to a meta-analysis amounting
to a frequency of 1.4%18 . More recently, Thompson et al. reported BRAF mutations in 7
CRCs from LS patients in the Colon CFR (cancer family registry) dataset and estimated a
probability of 2.9% for the presence of BRAF mutations in LS CRC19.
We hypothesized that the predictive value of BRAF V600E mutation for the exclusion of LS
may depend on the age at diagnosis. We analyzed LS- and population-based databases to
determine the prevalence of BRAF mutations and the presence of LS germline mutations in
patients of different age groups.

medRxiv preprint doi: https://doi.org/10.1101/19009274; this version posted October 16, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Methods
A general outline of the study design is provided in Figure 1 A.
BRAF mutation frequency in LS-associated CRC
Data on the BRAF mutation status of CRCs from LS patients with proven pathogenic germline
mutations in one of the MMR genes were obtained from the central database of the German
HNPCC Consortium. All patients provided informed and written consent. The study was
approved by the institutional Ethics Committee.
In addition, a literature database (NCBI PubMed, Feb 15, 2019) search for publications that
included information on the BRAF mutation status of MSI cancers from patients with proven
germline mutations in one of the MMR-genes or clinically diagnosed Lynch syndrome was
performed according to PRISMA guidelines (Figure 1 B). The search terms "BRAF AND Lynch
syndrome AND colorectal" were applied and 241 entries were found. 176 studies were
excluded by title. 38 studies were excluded after full review due to lacking information on
clinical or genetic data on LS or to the exclusion of patients with BRAF-mutant CRC from
germline testing. One of the remaining entries included a literature review (Parsons et al.
201217) on BRAF mutations in colorectal cancer. Full text review of all studies cited therein
revealed 4 studies suitable for integration into our analysis which had not already been
retrieved by our literature review. Among the remaining 30 publications those not providing
information on the gene affected by the germline mutation were included into the
calculation of the BRAF mutation frequency in LS-associated CRC in general, yet excluded
from the calculations of the BRAF mutation frequency in specific germline mutations.
Calculated age-specific prevalence of BRAF-mutant LS CRC among all CRCs
The age-specific prevalence of LS CRC was taken from the largest population-based study on
the topic2. LS CRC is here defined as a CRC developing in a proven LS germline mutation
carrier. Given the age categories published, the prevalence of LS CRC among all CRCs was
calculated for age categories â‰¤50, 51-60, 61-70, and >70. Since age categories slightly
differed from that used to determine the frequency of BRAF-mutant MSI CRC (<50, 50-59,
60-69, â‰¥70), we compared the age-specific prevalence of LS CRC found by Moreira et al.2
with that of 3 other population based studies using age categories <501,20,21, and 50-5921. As
no significant differences were observed, we used the age categories <50, 50-59, 60-69, and
â‰¥70 throughout our study.
The age-specific rate of BRAF-mutant LS CRC among all CRCs was calculated for each age
group using the definition of conditional probabilities:
ğ‘ƒ(ğµğ‘…ğ´ğ¹ğ‘šğ‘¢ğ‘¡, ğ¿ğ‘†|ğ¶ğ‘…ğ¶) = ğ‘ƒ(ğµğ‘…ğ´ğ¹ğ‘šğ‘¢ğ‘¡|ğ¿ğ‘†, ğ¶ğ‘…ğ¶) â‹… ğ‘ƒ(ğ¿ğ‘†|ğ¶ğ‘…ğ¶),
where ğ‘ƒ(ğµğ‘…ğ´ğ¹ğ‘šğ‘¢ğ‘¡|ğ¿ğ‘†, ğ¶ğ‘…ğ¶) is assumed to be constant for all age groups. Given a CRC, the
term ğ‘ƒ(ğµğ‘…ğ´ğ¹ğ‘šğ‘¢ğ‘¡, ğ¿ğ‘†|ğ¶ğ‘…ğ¶) describes the conditional probability that this CRC is BRAFmutant and LS-associated. The further probabilities are defined analogously.
Observed age-specific prevalence of BRAF mutations among MSI CRCs in population-based
cohorts

medRxiv preprint doi: https://doi.org/10.1101/19009274; this version posted October 16, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

To determine the age-specific prevalence of BRAF mutations in unselected CRC specimens,
we used information from the DACHS cohort study 22-24 and the DFCI database
(www.cbioportal.org, Jan 04, 2018)25-27. The age distribution of patients with MSI and BRAFmutant CRC was determined in comparison to the age distribution of patients with MSS
BRAF-wild type (BRAF-wt), MSS BRAF-mutant, MSI BRAF-wt CRCs. The results of MSI and
BRAF mutation typing in the DACHS cohort have been published in a previous study 28.
In addition, we performed a literature review (NCBI PubMed, Feb 15, 2019) of publications
that included information on the BRAF mutation status of MSI and MSS cancers according to
age groups (Figure 1 C). The search terms "BRAF AND population AND colorectal cancer AND
Lynch syndrome" and "BRAF AND population AND colorectal cancer AND microsatellite
instability were used. A total of 188 entries were retrieved. Among these, 157 studies mainly
reporting on cost effectiveness and degree of diagnostic application were excluded by title.
Of 31 entries with full text review 24 were excluded since the age specific prevalence of
molecular subtypes (MSI BRAF-mutant, MSI BRAF-wt, MSS BRAF-mutant, MSS BRAF-wt) was
not given. Owing to the major use of age categories <50, 50-59, 60-69, and â‰¥70 years for the
7 studies used we adapted information of both DACHS and DFCI database to these age
groups.
All 95% confidence intervals were calculated with the modified Wald method.
Calculation of potentially missed cases
By only testing BRAF-wt MSI CRCs for LS, a certain number ğ‘›ğ‘šğ‘–ğ‘ ğ‘ ğ‘’ğ‘‘ğ¶ğ‘ğ‘ ğ‘’ğ‘  of LS patients may
be missed. This corresponds to the number of BRAF-mutant LS CRC cases among all MSI
CRCs. It is computed for each age group by
ğ‘›ğ‘šğ‘–ğ‘ ğ‘ ğ‘’ğ‘‘ğ¶ğ‘ğ‘ ğ‘’ğ‘  = ğ‘›ğ‘€ğ‘†ğ¼ğ‘ƒğ‘ğ‘¡ğ‘–ğ‘’ğ‘›ğ‘¡ğ‘  â‹… ğ‘ƒ(ğµğ‘…ğ´ğ¹ğ‘šğ‘¢ğ‘¡, ğ¿ğ‘†|ğ‘€ğ‘†ğ¼, ğ¶ğ‘…ğ¶),
where ğ‘›ğ‘€ğ‘†ğ¼ğ‘ƒğ‘ğ‘¡ğ‘–ğ‘’ğ‘›ğ‘¡ğ‘  is assumed to be constant for each age group.
Given an MSI CRC, the term ğ‘ƒ(ğµğ‘…ğ´ğ¹ğ‘šğ‘¢ğ‘¡, ğ¿ğ‘†|ğ‘€ğ‘†ğ¼, ğ¶ğ‘…ğ¶) represents the conditional
probability that the given MSI CRC is BRAF-mutant and LS-associated.
By this and using the definition of conditional probabilities, we calculated
ğ‘ƒ(ğµğ‘…ğ´ğ¹ğ‘šğ‘¢ğ‘¡, ğ¿ğ‘†|ğ‘€ğ‘†ğ¼, ğ¶ğ‘…ğ¶) =

ğ‘ƒ(ğµğ‘…ğ´ğ¹ğ‘šğ‘¢ğ‘¡,ğ¿ğ‘†|ğ¶ğ‘…ğ¶)
ğ‘ƒ(ğ‘€ğ‘†ğ¼,ğ¶ğ‘…ğ¶)

.

The denominator is given by the observations from the literature reviews mentioned in the
previous section, namely by adding the frequencies of BRAF-mutant MSI CRCs and BRAF-wt
MSI CRCs among all CRCs
ğ‘ƒ(ğ‘€ğ‘†ğ¼|ğ¶ğ‘…ğ¶) = ğ‘ƒ(ğµğ‘…ğ´ğ¹ğ‘šğ‘¢ğ‘¡, ğ‘€ğ‘†ğ¼|ğ¶ğ‘…ğ¶) + ğ‘ƒ(ğµğ‘…ğ´ğ¹ğ‘¤ğ‘¡, ğ‘€ğ‘†ğ¼|ğ¶ğ‘…ğ¶).
Calculated percentage of MSI CRC excluded from MMR gene germline mutation analysis
due to BRAF mutation
Instead of performing a germline mutation analysis for all MSI CRC samples, we only test
BRAF-wt MSI CRCs for LS. Thus, the percentage of BRAF-mutant MSI CRCs among all MSI
CRCs is excluded from MMR gene germline mutation analysis, which can be computed by

medRxiv preprint doi: https://doi.org/10.1101/19009274; this version posted October 16, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

ğ‘ƒ(ğµğ‘…ğ´ğ¹ğ‘šğ‘¢ğ‘¡|ğ‘€ğ‘†ğ¼, ğ¶ğ‘…ğ¶) =

ğ‘ƒ(ğµğ‘…ğ´ğ¹ğ‘šğ‘¢ğ‘¡,ğ‘€ğ‘†ğ¼|ğ¶ğ‘…ğ¶)
ğ‘ƒ(ğ‘€ğ‘†ğ¼|ğ¶ğ‘…ğ¶)

.

Cost calculations for both diagnostic algorithms
We assumed a constant number of MSI CRC cases ğ‘›ğ‘€ğ‘†ğ¼ğ‘ƒğ‘ğ‘¡ğ‘–ğ‘’ğ‘›ğ‘¡ğ‘  to be tested in each age
group. By performing MMR gene germline analysis for all MSI CRCs, the following costs for
the first diagnostic algorithm will arise:
$ğ·ğ‘–ğ‘ğ‘”ğ‘›ğ‘œğ‘ ğ‘¡ğ‘–ğ‘1 = ğ‘›ğ‘€ğ‘†ğ¼ğ‘ƒğ‘ğ‘¡ğ‘–ğ‘’ğ‘›ğ‘¡ğ‘  â‹… $ğ‘”ğ‘’ğ‘Ÿğ‘šğ‘™ğ‘–ğ‘›ğ‘’ğ´ğ‘›ğ‘ğ‘™ğ‘¦ğ‘ ğ‘–ğ‘  ,
which is constant for all age groups due to our assumptions.
For the second diagnostic algorithm, all MSI CRCs are first tested for BRAF mutations. Then,
only for the BRAF-wt MSI CRCs MMR gene germline analysis is performed. This leads to the
following costs:
$ğ·ğ‘–ğ‘ğ‘”ğ‘›ğ‘œğ‘ ğ‘¡ğ‘–ğ‘2 = ğ‘›ğ‘€ğ‘†ğ¼ğ‘ƒğ‘ğ‘¡ğ‘–ğ‘’ğ‘›ğ‘¡ğ‘  â‹… ($ğµğ‘…ğ´ğ¹ğ‘¡ğ‘’ğ‘ ğ‘¡ğ‘–ğ‘›ğ‘” + ğ‘ƒ(ğµğ‘…ğ´ğ¹ğ‘¤ğ‘¡|ğ‘€ğ‘†ğ¼, ğ¶ğ‘…ğ¶) â‹… $ğ‘”ğ‘’ğ‘Ÿğ‘šğ‘™ğ‘–ğ‘›ğ‘’ğ´ğ‘›ğ‘ğ‘™ğ‘¦ğ‘ ğ‘–ğ‘  ),
which we calculated for different cost ratios of germline analysis and BRAF testing
ğ‘=

$ğ‘”ğ‘’ğ‘Ÿğ‘šğ‘™ğ‘–ğ‘›ğ‘’ğ´ğ‘›ğ‘ğ‘™ğ‘¦ğ‘ ğ‘–ğ‘ 
$ğµğ‘…ğ´ğ¹ğ‘¡ğ‘’ğ‘ ğ‘¡ğ‘–ğ‘›ğ‘”

âˆˆ [2.5,100].

medRxiv preprint doi: https://doi.org/10.1101/19009274; this version posted October 16, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Results
Prevalence of BRAF mutations in LS CRCs
In the present study (see Figure 1A for the study outline), we first aimed to determine the
BRAF mutation prevalence in patients with LS CRC. Data on the BRAF mutation status of 98
CRCs from proven carriers of a pathogenic LS germline mutation were available in the
German HNPCC Consortium 29,30. Those comprised 74 MLH1, 14 MSH2, 4 MSH6, and 6 PMS2
mutation carriers. Two BRAF-mutant CRCs were identified (2.0%, 95% CI: 0.1-7.6%): one in
an MLH1-deficient (1.3%, 1/74) and one in an MSH2-deficient (7.1%, 1/14) cancer. Both
patients were <50 years at the time of CRC diagnosis.
To validate these results, a literature search was performed to determine BRAF mutation
prevalence in LS-associated CRC (Figure 1B). The literature review revealed 30 publications
with data on BRAF mutations in LS-associated CRC. BRAF mutation data were retrieved for
969 LS CRCs, and data on the MMR gene affected in the germline were available for 832 of
them (Table 1). BRAF mutations were reported in 9 studies for 15 cancers, encompassing 8
MLH1-deficient (including one germline epimutation carrier31), 2 MSH2-deficient and 5
PMS2-deficient CRC (Table 1, Supplementary Table 1).
The overall frequency of BRAF mutations in LS was 1.6% (15/969, 95% CI: 0.9-2.6%), with a
frequency of 1.7% (95% CI: 0.8-3.3%) among MLH1-deficient CRCs (8/482), 0.7% (95% CI: 02.9%) among MSH2-deficient (2/269), and 9.3% (95% CI: 3.6-20.3%) among PMS2-deficient
CRCs (5/54). No BRAF mutations (0%, 95% CI: 0-14.8%) were found among CRCs from MSH6
mutation carriers (0/27). Among BRAF-mutant LS-associated CRCs, data on age at diagnosis
was available for 7 patients (4 MLH1, 1 MSH2, 2 PMS2 mutation carriers). All except one
mutation carrier with a PMS2 germline mutation were <50 years.
Age-specific prevalence of BRAF mutations in MSI CRCs
To analyze the age-specific prevalence of BRAF mutations in MSI CRCs we used two
independent cohorts: population-based DACHS cohort 22-24 and publicly available DFCI set2527.
Data on BRAF mutation and MSI status in the DACHS cohort were available for 2046
patients, of which 93 were found to have BRAF-mutant MSI CRC. BRAF-mutant MSI CRC was
associated with advanced age in this cohort (median age 75). From 93 BRAF-mutant MSI
CRCs, 90 (96.8%) were from patients â‰¥60. The prevalence of BRAF mutations in MSI CRCs
ğ‘ƒ(ğµğ‘…ğ´ğ¹ğ‘šğ‘¢ğ‘¡|ğ‘€ğ‘†ğ¼, ğ¶ğ‘…ğ¶) of the different age groups were 0 (0%) out of 14 in patients <50, 3
(12.0%) out of 25 in patients 50-59, 25 (41.7%) out of 60 in patients 60-69, and 65 (50.8%)
out of 128 in patients â‰¥70 years at diagnosis (Supplementary Table 2, 3).
For independent validation, we next analyzed the age-specific prevalence of BRAF mutations
in MSI CRC using DFCI cohort. Here, data on BRAF mutation and MSI status were available
for 528 patients, 53 of which had a BRAF-mutant MSI CRC. The association of BRAF with
older age could be confirmed: median age of patients with BRAF-mutant MSI CRC was 73
years, with 51 out of 53 patients (96.2%) being â‰¥60. Notably, in both cohorts combined, 141
(96.6%) out of 146 BRAF-mutant MSI CRCs were from the group of patients â‰¥60
(Supplementary Table 2, 3).

medRxiv preprint doi: https://doi.org/10.1101/19009274; this version posted October 16, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

To increase the representativeness of the age-specific prevalence of BRAF-mutant MSI CRC
among all MSI CRC and further validate the obtained results, we combined the DACHS and
DFCI data with the results of 7 previously published studies providing information on the
age-dependent prevalence of BRAF mutations in MSI CRC (Figure 1C, Supplementary Table
3).
Among unselected MSI CRCs, BRAF mutation frequency ğ‘ƒ(ğµğ‘…ğ´ğ¹ğ‘šğ‘¢ğ‘¡|ğ‘€ğ‘†ğ¼, ğ¶ğ‘…ğ¶) was 1.6%
(2/124) in patients <50, 20.2% (24/119) in those 50-59, 59.2% (109/184) in those 60-69, and
62.0% (204/329) in patients â‰¥70. 92.3% (313/339) of BRAF mutations were observed in
patients >60, whereas only 0.6% (2/339) were documented in patients <50, consistent with
our findings from public datasets (Supplementary Table 3).
Among all CRCs, the overall prevalence of BRAF-mutant MSI cancers
ğ‘ƒ(ğµğ‘…ğ´ğ¹ğ‘šğ‘¢ğ‘¡, ğ‘€ğ‘†ğ¼|ğ¶ğ‘…ğ¶) was 0.2% (2/1096) in patients <50, 1.4% (24/1731) in those 50-59,
6.8% (109/1607) in those 60-69, and 8.4% (204/2441) in those â‰¥70 years (Figure 2,
Supplementary Table 3).
Comparison of the calculated number of BRAF-mutant LS CRC and the number of actually
identified BRAF-mutant MSI CRCs according to age groups
According to population-based data2, the age-specific prevalence of LS in CRC patients
ğ‘ƒ(ğ¿ğ‘†|ğ¶ğ‘…ğ¶) is 8.4%, 2.9%, 1.4%, and 0.8% for patients â‰¤50, 51-60, 61-70, and â‰¥71,
respectively. These data indicate that in contrast to the frequency of BRAF-mutant MSI CRCs
among all CRCs, which increases with age, the prevalence of LS among all CRC patients
decreases with age (Figure 2).
To estimate the potential risk of missing LS by applying BRAF mutation testing in MSI CRCs of
the different age groups, we used the calculated frequency of BRAF-mutant LS CRC among
all CRC ğ‘ƒ(ğµğ‘…ğ´ğ¹ğ‘šğ‘¢ğ‘¡, ğ¿ğ‘†|ğ¶ğ‘…ğ¶) for the considered age groups and applied it to the number
of patients observed in the age-specific MSI and BRAF-typed cohorts. Using this approach,
we compared the calculated number of BRAF-mutant LS CRC cases with the observed
number for each age group: In patients 60-69 and â‰¥70, the calculated number of possible
BRAF-mutant LS CRC was very low compared to the number of observed BRAF-mutant MSI
CRCs (0.4 vs. 109 and 0.3 vs. 204, respectively), indicating that the risk of false-negative
results for LS detection by BRAF mutation testing is very low in these age groups. However,
in patients <50, the calculated number of BRAF-mutant LS CRC almost equaled the number
of observed BRAF-mutant MSI CRCs (1.5 vs. 2), suggesting a considerable risk of falsenegative LS detection if BRAF mutation testing is applied (Table 2).
The calculated risk of potentially missed cases according to age groups
Further, the percentage ğ‘ƒ(ğµğ‘…ğ´ğ¹ğ‘šğ‘¢ğ‘¡, ğ¿ğ‘†|ğ‘€ğ‘†ğ¼, ğ¶ğ‘…ğ¶) of MSI CRCs potentially excluded from
MMR gene germline mutation analysis due to BRAF mutation is also age-dependent. In
patients <50 years only 1.6% of all MSI CRCs are BRAF-mutant, meaning that here only for a
very minor proportion of patients the efforts and costs of further MMR gene germline
analysis can be saved. However, this proportion increases with age, i.e. in patients 50-59
20.2%, in patients 60-69 59.2% and in patients â‰¥70 62.0% of germline analyses can be saved
(Figure 3).

medRxiv preprint doi: https://doi.org/10.1101/19009274; this version posted October 16, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Cost efficiency of BRAF mutation testing according to age groups
We calculated the relative costs of performing BRAF mutation testing of all MSI CRCs
followed by MMR gene germline analysis for BRAF-wt MSI CRCs only (diagnostic algorithm 2,
see Methods), accounting for a range of possible cost ratios between BRAF mutation testing
and MMR gene germline sequencing. As a reference, we always used the diagnostic
algorithm 1 of performing MMR gene germline analysis for all MSI CRC patients (Figure 4). In
general, the costs for diagnostic algorithm 2 $ğ·ğ‘–ğ‘ğ‘”ğ‘›ğ‘œğ‘ ğ‘¡ğ‘–ğ‘2 decrease with age (Figures 4A, 4B).
Considering different cost ratios for BRAF mutation testing and germline analysis, the overall
costs for diagnostic algorithm 2 are lowest if BRAF mutation testing is cheap (Figures 4A, 4C).
Importantly, in patients <50 algorithm 2 does not save costs for any considered cost ratio. In
patients >60 years, the BRAF mutation testing leads to a cost reduction for all cost ratios
with most pronounced effects in MSI CRC patients â‰¥70 (Figures 4A, 4B), whereas in patients
diagnosed in the range of 50-59 years the cost efficiency of BRAF mutation testing depends
on the cost ratio.

medRxiv preprint doi: https://doi.org/10.1101/19009274; this version posted October 16, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Discussion
In the present study we analyzed the age-dependent efficacy of BRAF mutation testing for
the exclusion of LS, including cost efficiency calculations and possible false-negative result
rates. The results of the present study for the first time demonstrate that BRAF mutation
testing in patients below the age of 50 is not justified.
We found that 92.3% of the MSI CRCs with a BRAF mutation were diagnosed in patients >60.
Only 0.6% of BRAF mutations in MSI CRCs were detected in patients <50. As the percentage
of BRAF-mutant tumors among MSI CRCs diagnosed in patients <50 was 1.6%, more than 60
tumors need to be tested to identify one BRAF mutation. Evidently, BRAF mutation testing is
not cost-effective in this age group, but may substantially delay the LS diagnostics flow.
We analyzed two independent cohorts (DACHS and DFCI) and further validated the findings
by a systematic literature review. Notably, data from a total of 6875 CRC patients showed a
very high congruency of age distributions between all examined data sources, supporting the
strong association of BRAF mutations in MSI CRC patients with advanced age at diagnosis.
Our data also demonstrate that BRAF mutation testing in patients <50 has a substantial risk
of erroneously excluding LS mutation carriers from further germline MMR gene diagnostics
and genetic counseling: First, reports of BRAF mutations occurring in MSI CRCs from LS
germline mutation carriers often refer to patients <50; second, the calculated frequency of
BRAF-mutant tumors in LS CRCs from patients <50 closely matches the observed frequency
of BRAF mutations in MSI CRCs of the same age group, suggesting a substantial overlap and
the risk of missing patients who have LS. The number of missed LS cases due to BRAF
mutation testing might even be underestimated, as BRAF mutation status may have been
used to exclude LS in some of the included studies. Prospectively, studies applying universal
germline mutation analyses without pre-selecting based on BRAF status are highly
encouraged in order to identify the true proportion of BRAF-mutant LS tumors.
Even if patients <50 with a BRAF-mutant MSI CRC may not have LS, they may still suffer from
other inherited tumor syndromes. Serrated polyposis syndrome (SPS) is an as yet
incompletely understood disease associated in part with germline mutations in senescencerelated and DNA damage response genes, such as RNF4332,33. Cancers in SPS frequently
follow the same BRAF-mutant and MLH1-silencing pathway as sporadic late age at onset
CRCs34,35. SPS, formerly known as hyperplastic polyposis syndrome, is still underdiagnosed.
Therefore, thorough genetic counseling and diagnostics is encouraged in MSI CRC patients
<50 with BRAF mutations, instead of excluding them from germline analysis for hereditary
CRC.
Whereas BRAF mutation testing, independent from the applied method, clearly is not costeffective in MSI CRC patients <50, the situation in patients between 50 and 60 is less clear.
Here, a potential cost reduction depends on the relative cost ratios between BRAF mutation
testing and MMR gene germline mutation. Using a wide range of cost ratios between these
two analyses, we found that a cost reduction can be achieved in patients between 50 and 60
years whenever BRAF mutation testing costs less than 20% of the price for MMR gene
germline mutation analysis.

medRxiv preprint doi: https://doi.org/10.1101/19009274; this version posted October 16, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

For patients >60, we could confirm previous reports suggesting BRAF mutation testing as a
useful tool in LS diagnostics: Here, BRAF mutation testing has a low risk of erroneously
excluding LS patients from germline MMR gene mutation analysis, but offers a significant
cost reduction across all cost ratio scenarios.
Our study has strengths and limitations. Strength is the large number of data from CRCs
collected in population-based cohorts mirroring the situation in daily practice. Moreover,
our study for the first time dissects the efficacy and appropriateness of BRAF mutation
testing for the exclusion of LS according to patientsâ€™ age. In addition, we provide cost
efficiency estimation for the inclusion of BRAF mutation testing of MSI CRCs in LS diagnostic
algorithms by relating the cost increase inferred by BRAF mutation testing to the potentially
saved costs of MMR gene germline mutation testing.
One limitation of our study is our presumption that the BRAF mutation frequency in LS CRC
remains stable over time. We could not deduce more precise estimates from the so far
published literature, as published data were not specific enough. Some overlaps of tumors
reported in different studies can also not fully be excluded. In addition, for all cost
calculations we had to assume application of BRAF mutation testing for all MSI CRCs, not for
MLH1-deficient CRCs only, as data in the literature on MMR protein status was absent for a
substantial number of tumors. As the majority of MSI CRCs from older patients are MLH1deficient36 this does not have a major effect here. In young patients, however, only about
50% of MSI CRCs are MLH1-deficient21,37,38. Using BRAF mutation testing for the exclusion of
LS only selectively in MLH1-deficient cancers would therefore approximately halve the
additional costs introduced by BRAF mutation testing in the LS diagnostic algorithm,
however, not alter the limited value of BRAF mutation testing because of the virtual absence
of BRAF mutations in young patients.
In conclusion, our data show that BRAF mutation testing for the exclusion of LS is costinefficient and misleading in MSI CRC patients <50 years, although being effective in older
age groups. We recommend reconsidering LS diagnostic guidelines, directly channeling MSI
CRC patients <50 years to genetic counselling without prior BRAF mutation testing.

medRxiv preprint doi: https://doi.org/10.1101/19009274; this version posted October 16, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Acknowledgments:
The excellent technical assistance provided by Petra HÃ¶fler and Nina Nelius are gratefully
acknowledged.

medRxiv preprint doi: https://doi.org/10.1101/19009274; this version posted October 16, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

References:
1.
Salovaara R, Loukola A, Kristo P, et al: Population-based molecular detection
of hereditary nonpolyposis colorectal cancer. J Clin Oncol 18:2193-200, 2000
2.
Moreira L, Balaguer F, Lindor N, et al: Identification of Lynch syndrome among
patients with colorectal cancer. Jama 308:1555-65, 2012
3.
de la Chapelle A: Microsatellite instability. N Engl J Med 349:209-10, 2003
4.
Umar A, Boland CR, Terdiman JP, et al: Revised Bethesda Guidelines for
hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J
Natl Cancer Inst 96:261-8, 2004
5.
Phipps AI, Limburg PJ, Baron JA, et al: Association between molecular
subtypes of colorectal cancer and patient survival. Gastroenterology 148:77-87.e2, 2015
6.
Leggett B, Whitehall V: Role of the serrated pathway in colorectal cancer
pathogenesis. Gastroenterology 138:2088-100, 2010
7.
Vasen HF, Moslein G, Alonso A, et al: Guidelines for the clinical management
of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 44:353-62, 2007
8.
Boland CR, Thibodeau SN, Hamilton SR, et al: A National Cancer Institute
Workshop on Microsatellite Instability for cancer detection and familial predisposition:
development of international criteria for the determination of microsatellite instability in
colorectal cancer. Cancer Res 58:5248-57, 1998
9.
Vasen HF, Blanco I, Aktan-Collan K, et al: Revised guidelines for the clinical
management of Lynch syndrome (HNPCC): recommendations by a group of European
experts. Gut 62:812-23, 2013
10.
Giardiello FM, Allen JI, Axilbund JE, et al: Guidelines on genetic evaluation and
management of Lynch syndrome: a consensus statement by the US Multi-society Task Force
on colorectal cancer. Am J Gastroenterol 109:1159-79, 2014
11.
Domingo E, Laiho P, Ollikainen M, et al: BRAF screening as a low-cost effective
strategy for simplifying HNPCC genetic testing. J Med Genet 41:664-8, 2004
12.
Deng G, Bell I, Crawley S, et al: BRAF mutation is frequently present in
sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis
colorectal cancer. Clin Cancer Res 10:191-5, 2004
13.
Loughrey MB, Waring PM, Tan A, et al: Incorporation of somatic BRAF
mutation testing into an algorithm for the investigation of hereditary non-polyposis
colorectal cancer. Fam Cancer 6:301-10, 2007
14.
Miyaki M, Iijima T, Yamaguchi T, et al: Both BRAF and KRAS mutations are rare
in colorectal carcinomas from patients with hereditary nonpolyposis colorectal cancer.
Cancer Lett 211:105-9, 2004
15.
Newton K, Jorgensen NM, Wallace AJ, et al: Tumour MLH1 promoter region
methylation testing is an effective prescreen for Lynch Syndrome (HNPCC). J Med Genet
51:789-96, 2014
16.
Lagerstedt Robinson K, Liu T, Vandrovcova J, et al: Lynch syndrome
(hereditary nonpolyposis colorectal cancer) diagnostics. J Natl Cancer Inst 99:291-9, 2007
17.
Walsh MD, Buchanan DD, Walters R, et al: Analysis of families with Lynch
syndrome complicated by advanced serrated neoplasia: the importance of pathology review
and pedigree analysis. Fam Cancer 8:313-23, 2009
18.
Parsons MT, Buchanan DD, Thompson B, et al: Correlation of tumour BRAF
mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation
status: a literature review assessing utility of tumour features for MMR variant classification.
J Med Genet 49:151-7, 2012

medRxiv preprint doi: https://doi.org/10.1101/19009274; this version posted October 16, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

19.
Thompson BA, Goldgar DE, Paterson C, et al: A multifactorial likelihood model
for MMR gene variant classification incorporating probabilities based on sequence
bioinformatics and tumor characteristics: a report from the Colon Cancer Family Registry.
Hum Mutat 34:200-9, 2013
20.
Aaltonen LA, Salovaara R, Kristo P, et al: Incidence of hereditary nonpolyposis
colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med
338:1481-7, 1998
21.
Schofield L, Watson N, Grieu F, et al: Population-based detection of Lynch
syndrome in young colorectal cancer patients using microsatellite instability as the initial
test. Int J Cancer 124:1097-102, 2009
22.
Brenner H, Jansen L, Ulrich A, et al: Survival of patients with symptom- and
screening-detected colorectal cancer. Oncotarget 7:44695-44704, 2016
23.
Hoffmeister M, Jansen L, Rudolph A, et al: Statin use and survival after
colorectal cancer: the importance of comprehensive confounder adjustment. J Natl Cancer
Inst 107:djv045, 2015
24.
Brenner H, Chang-Claude J, Jansen L, et al: Reduced risk of colorectal cancer
up to 10 years after screening, surveillance, or diagnostic colonoscopy. Gastroenterology
146:709-17, 2014
25.
Giannakis M, Mu XJ, Shukla SA, et al: Genomic Correlates of Immune-Cell
Infiltrates in Colorectal Carcinoma. Cell Rep 15:857-865, 2016
26.
Cerami E, Gao J, Dogrusoz U, et al: The cBio cancer genomics portal: an open
platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401-4, 2012
27.
Gao J, Aksoy BA, Dogrusoz U, et al: Integrative analysis of complex cancer
genomics and clinical profiles using the cBioPortal. Sci Signal 6:pl1, 2013
28.
Blaker H, Alwers E, Arnold A, et al: The Association Between Mutations in
BRAF and Colorectal Cancer-Specific Survival Depends on Microsatellite Status and Tumor
Stage. Clin Gastroenterol Hepatol, 2018
29.
Engel C, Vasen HF, Seppala T, et al: No Difference in Colorectal Cancer
Incidence or Stage at Detection by Colonoscopy Among 3 Countries With Different Lynch
Syndrome Surveillance Policies. Gastroenterology 155:1400-1409 e2, 2018
30.
Morak M, Ibisler A, Keller G, et al: Comprehensive analysis of the MLH1
promoter region in 480 patients with colorectal cancer and 1150 controls reveals new
variants including one with a heritable constitutional MLH1 epimutation. J Med Genet
55:240-248, 2018
31.
Goel A, Nguyen TP, Leung HC, et al: De novo constitutional MLH1
epimutations confer early-onset colorectal cancer in two new sporadic Lynch syndrome
cases, with derivation of the epimutation on the paternal allele in one. Int J Cancer 128:86978, 2011
32.
Gala MK, Mizukami Y, Le LP, et al: Germline mutations in oncogene-induced
senescence pathways are associated with multiple sessile serrated adenomas.
Gastroenterology 146:520-9, 2014
33.
Egoavil C, Juarez M, Guarinos C, et al: Increased Risk of Colorectal Cancer in
Patients With Multiple Serrated Polyps and Their First-Degree Relatives. Gastroenterology
153:106-112.e2, 2017
34.
Edelstein DL, Cruz-Correa M, Soto-Salgado M, et al: Risk of Colorectal and
Other Cancers in Patients With Serrated Polyposis. Clin Gastroenterol Hepatol 13:1697-9,
2015

medRxiv preprint doi: https://doi.org/10.1101/19009274; this version posted October 16, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

35.
He EY, Wyld L, Sloane MA, et al: The molecular characteristics of colonic
neoplasms in serrated polyposis: a systematic review and meta-analysis. J Pathol Clin Res
2:127-37, 2016
36.
Sinicrope FA, Sargent DJ: Clinical implications of microsatellite instability in
sporadic colon cancers. Curr Opin Oncol 21:369-73, 2009
37.
Giraldez MD, Balaguer F, Bujanda L, et al: MSH6 and MUTYH deficiency is a
frequent event in early-onset colorectal cancer. Clin Cancer Res 16:5402-13, 2010
38.
Goshayeshi L, Ghaffarzadegan K, Khooei A, et al: Prevalence and
clinicopathological characteristics of mismatch repair-deficient colorectal carcinoma in early
onset cases as compared with late-onset cases: a retrospective cross-sectional study in
Northeastern Iran. BMJ Open 8:e023102, 2018

medRxiv preprint doi: https://doi.org/10.1101/19009274; this version posted October 16, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Tables
Table 1: BRAF mutation prevalence in LS-associated CRC. Data from the German HNPCC
Consortium and summarized data from 30 studies found in the literature (detailed in suppl.
table 1). *Information on MMR gene affected by germline mutation in 832 of the 969 cases.
LS: Lynch syndrome. Not reported â€“ MMR gene affected by germline mutation was not
specified.
All LS

MLH1

MSH2

MSH6

not
reported

PMS2

German HNPCC database

98

74

14

4

6

0

Literature (30 studies)

871

408

255

23

48

137

Total

969*

482

269

27

54

137

BRAF mutations

15 (1.6%)

8 (1.7%)

2 (0.7%)

0

5 (9.3%)

0

Table 2: Comparison of the calculated number of BRAF-mutant LS CRC and the number of
actually identified BRAF-mutant MSI CRCs according to age groups. The number of LS CRC
was deduced from LS prevalence data of a population based study 2, the number of BRAFmutant LS CRC was calculated presuming a BRAF mutation frequency of 1.6%. For
comparison the number of MSI and BRAF-mutant CRC actually observed in the age-specific
cohorts was determined.
Age group

<50

50-59

60-69

>69

Total number of CRC cases

1096

1731

1607

2441

92

50

22

20

1.5

0.8

0.4

0.3

2

24

109

204

ğ‘›ğ¶ğ‘…ğ¶ (MSS+MSI)
Calculated LS CRCs
ğ‘›ğ¶ğ‘…ğ¶ âˆ™ ğ‘ƒ(ğ¿ğ‘†|ğ¶ğ‘…ğ¶)
Calculated LS CRCs with BRAF mut
ğ‘›ğ¶ğ‘…ğ¶ âˆ™ ğ‘ƒ(ğµğ‘…ğ´ğ¹ğ‘šğ‘¢ğ‘¡, ğ¿ğ‘†|ğ¶ğ‘…ğ¶)
Observed MSI CRCs with BRAF mut
ğ‘›ğ¶ğ‘…ğ¶ âˆ™ ğ‘ƒ(ğµğ‘…ğ´ğ¹ğ‘šğ‘¢ğ‘¡, ğ‘€ğ‘†ğ¼|ğ¶ğ‘…ğ¶)

medRxiv preprint doi: https://doi.org/10.1101/19009274; this version posted October 16, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Figures

Figure 1. Study design and literature review workflows. A. Flow diagram for the calculation of the
sensitivity and cost efficiency of BRAF mutation testing of MSI CRCs in LS diagnostics. B. Schematic
illustration of the literature search performed as described in details in Methods section in order to
determine BRAF mutation frequency in LS-associated CRC. C. Schematic illustration of the literature
search of publications that included information on the BRAF mutation status of MSI and MSS
cancers according to age groups performed as described in details in Methods section (Figure 1 C).

medRxiv preprint doi: https://doi.org/10.1101/19009274; this version posted October 16, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

14%
MSI CRC among all CRC
12%
10%
BRAF- mut. MSI CRC among all CRC

8%
6%
4%
2%
< 50

50- 59

60- 69

70

LS CRC among all CRC
age groups

Figure 2. Age-specific prevalence of MSI CRC (blue), LS-associated MSI CRC (gray), and BRAFmutant MSI CRC (red) among all CRC. Blue: The age-specific frequency of MSI CRCs among all CRCs
was calculated from the sum of BRAF-mutant and BRAF-wt MSI CRC frequencies for the different age
groups. Gray: Data for the prevalence of LS associated CRCs among all CRCs were obtained from
Moreira et al. 2. Red: Prevalence of BRAF-mutant MSI CRCs among all CRCs have been calculated from
literature and database data (Table 2).

medRxiv preprint doi: https://doi.org/10.1101/19009274; this version posted October 16, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

A.

1.2%
1.0%
0.8%
0.6%
0.4%
0.2%

< 50

B.

50- 59

60- 69

70

percentage of tests

age groups

germline mutation analysis

100%

for all MSI CRC samples

80%
exclusion from germline mutation analysis
60%

due to BRAF- mutation

40%
20%
< 50

50- 59

60- 69

70

age groups

Figure 3. Performance of BRAF mutation testing for the exclusion of Lynch syndrome according to
age groups. A. Calculated number of potentially missed LS cases. Assuming a constant rate of BRAF
mutations in LS-associated MSI CRCs over all age groups, the proportion of potentially missed LS
mutation carriers is low in higher age groups. In patients younger than 60 years at diagnosis, the risk
of missing LS by using BRAF mutation testing for the exclusion of LS increases (1.2% in patients < 50
years). B. Percentage of MSI CRC excluded from MMR gene germline mutation analysis due to BRAF
mutation. BRAF mutation testing of MSI CRC only leads to a marginal reduction of MMR gene
germline mutation analysis in younger age groups (1.6% in patients < 50 years), whereas a substantial
reduction of required analyses is achieved in older age groups (62.0% in patients â‰¥ 70 years). Number
of MMR gene germline mutation analysis for all MSI CRCs is used as a reference (100%, red line).

medRxiv preprint doi: https://doi.org/10.1101/19009274; this version posted October 16, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

A.

B.

C.

relative costs

relative costs

140%

140%

120%

120%

100%

100%

80%

1:2.5

80%

60%

1:5
1:10
1:40
1:100

40%

< 50
50- 59

60%
60- 69
70

40%
20%

20%
< 50

50- 59

60- 69

70

age groups

1:5 1:10 1:20 1:30 1:40 1:50 1:60 1:70 1:80 1:90 1:100

cost ratio

Figure 4. Cost calculation for both diagnostic algorithms, either performing MMR gene germline
mutation analysis for all MSI CRC patients (A. reference plane, B and C. red line), or performing
BRAF mutation testing of all MSI CRCs followed by MMR gene germline mutation analysis for
BRAF-wt MSI CRCs only (A: mountain surface, B and C: gray lines). A. 3D contour plot for all age
groups and cost ratios. B. Selective illustration for different cost ratios. C. Selective illustration of cost
performance for distinct age groups. Whereas BRAF mutations lead to a significant reduction of LS
diagnostics in older age groups, the implementation of BRAF mutation testing for exclusion of LS in
patients younger than 60 years at diagnosis leads to a cost increase for most scenarios of BRAF
mutation costs relative to costs of MMR gene germline mutation analysis. In addition to failure of
BRAF mutation testing with regard to cost reduction, implementation of BRAF mutation testing in
patients younger than 60 years also has the risk of missing hereditary cancer patients (see also Figure
2).

